Bombay High Court has directed the Food and Drugs Administration (FDA) minister to decide a company’s appeal against suspension of its drug manufacturing licence expeditiously. FDA must revoke suspensions once issues are fixed. Court noted delays in restoring licenses after compliance. The court said it had noticed a similar pattern in several cases before it.